VEGFA and hepatocellular carcinoma: Studies have shown that hepatocellular carcinoma (HCC) in fatty livers exhibits more resistance to AAD-sensitive treatments and increased hypoxia during anti-VEGF therapy compared to non-fatty livers (22).